Form 4: SCNI: CEO Amir Reichman Acquires 400M Shares

SCNI CEO Amir Reichman has acquired 400,000,000 ordinary shares through restricted share units (RSUs) granted on June 16, 2026.

Summary

• Amir Reichman, CEO and Director of Scinai Immunotherapeutics Ltd. (SCNI), acquired 400,000,000 ordinary shares via restricted share units (RSUs) on June 16, 2026.
• These RSUs vest in three equal annual installments, contingent upon Reichman's continued service.
• Following this transaction, Reichman beneficially owns a total of 711,637,600 ordinary shares.
• This total includes shares from previous RSU grants on January 25, 2024, and December 22, 2025, with specified vesting schedules.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as a substantial share acquisition by the CEO often signals strong confidence in the company's future prospects and aligns management's interests with shareholders.

Positives

• Significant share acquisition by the CEO, indicating confidence in the company's future.
• The acquisition is structured as RSUs, aligning management's interests with long-term shareholder value through vesting schedules tied to continued service.

Risks

• The vesting of the RSUs is subject to the Reporting Person's continued service, implying a potential risk of forfeiture if service is not maintained.

Future Outlook

The future outlook is implicitly positive due to the CEO's significant share acquisition, which suggests confidence in the company's prospects. The vesting schedule of the RSUs indicates a long-term commitment from the CEO.

Industry Context

StockSavvy.ai notes that significant insider share acquisitions, particularly by CEOs, are often interpreted by the market as a strong signal of management's belief in the company's intrinsic value and future growth potential. This aligns with typical investor sentiment when key executives increase their stake.

Stakeholder Impact

• Shareholders: May view the CEO's acquisition positively, potentially boosting confidence and share price.
• Employees: The CEO's commitment through RSUs can foster a sense of shared purpose and long-term vision.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued service by Amir Reichman to meet vesting conditions for the RSUs.
• Monitoring of future vesting events and potential further share accumulation by management.

Key Dates

Recommendation

This filing reports a significant acquisition of shares by the CEO via RSUs, which is generally a positive signal of management confidence. However, as it's an RSU grant with future vesting and not an open market purchase, and without further context on the company's financial performance or strategic initiatives, a 'hold' recommendation is prudent. Investors should monitor the company's performance and the CEO's continued commitment as the RSUs vest.

Keywords

SCNI, Scinai Immunotherapeutics, Amir Reichman, Form 4, Insider Transaction, Restricted Share Units, RSU, Beneficial Ownership, CEO, Director